Baxter International

Strategic Intent

Baxter International is a global medical technology leader that manufactures and distributes a broad portfolio of essential healthcare products, including intravenous (IV) solutions, infusion systems, clinical nutrition, and surgical technologies across hospital and home care settings.

Key Market Signals

• 2026-02: Layoff of 90 employees (3% of staff) at Marion, NC facility due to stabilized lower demand post-shortage.
• 2025-07: FDA issues Class I recall for Novum IQ Large Volume Pumps following 79 reports of serious injury and 2 deaths.
• 2025-02: Completion of Vantive (Kidney Care) spinoff to Carlyle for $3.8 billion.
• 2024-10: SEC issues order approving $18M Fair Fund distribution to investors following historical FX accounting violations.
• 2024-09: Hurricane Helene flooding forces closure of North Cove plant, triggering a national IV fluid supply crisis.

Financial Health

• 2024 full-year sales from continuing operations totaled $10.64 billion, representing a 3% increase on a reported basis (Source: https://www.baxter.com/baxter-newsroom/baxter-reports-fourth-quarter-and-full-year-2024-results)
• Completed the $3.8 billion divestiture of its Kidney Care business (Vantive) to Carlyle in early 2025 to reduce debt and streamline operations (Source: https://www.bakermckenzie.com/en/newsroom/2024/08/baxter-divestiture-of-vantive-kidney-care-segment)
• Projected full-year 2025 sales growth of 4% to 5% on a reported basis, despite operational impacts from natural disasters (Source: https://www.medicaleconomics.com/view/baxter-reports-5-revenue-growth-in-q3-as-new-ceo-launches-improvement-effort)

Impact & Compliance

Legal & Risks

Baxter faces significant litigation and regulatory risk in 2025-2026 related to a Class I recall of its Novum IQ infusion pumps following reports of patient injuries and fatalities, alongside associated securities fraud class action lawsuits.

Forensic Audit — 2 findings

• Class I recall of Novum IQ Large Volume Pumps in July 2025 due to software defects causing over-infusion or under-infusi...
• SEC Fair Fund administration update in October 2024 regarding $18M penalty for improper FX accounting transactions.

Classifications

Proprietary Analysis